Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Posttraumatic stress disorder (PTSD) is a prevalent psychiatric diagnosis among veterans and has high comorbidity with other medical and psychiatric conditions. This article reviews the pharmacotherapy recommendations from the 2010 revised Department of Veterans Affairs/Department of Defense Clinical Practice Guideline (CPG) for PTSD and provides practical PTSD treatment recommendations for clinicians. While evidence-based, trauma-focused psychotherapy is the preferred treatment for PTSD, pharmacotherapy is also an important treatment option. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors and the selective serotonin-norepinephrine reuptake inhibitor venlafaxine. Second-line agents have less evidence for their usefulness in PTSD and carry a potentially greater side effect burden. They include nefazodone, mirtazapine, tricyclic antidepressants, and monoamine oxidase inhibitors. Prazosin is beneficial for nightmares. Benzodiazepines and antipsychotics, either as monotherapy or used adjunctively, are not recommended in the treatment of PTSD. Treating co-occurring disorders, such as major depressive disorder, substance use disorders, and traumatic brain injury, is essential in maximizing treatment outcomes in PTSD. The CPG provides evidence-based treatment recommendations for treating PTSD with and without such co-occurring disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults
Brewin, C. R., Andrews, B., & Valentine, J. D. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.748 · Cited by 5,243 · cited 1×
“While most traumatized individuals do not develop PTSD, the incidence of PTSD varies and is influenced by a complex interaction of individual factors such as genetic predisposition and sex, with mediating factors such as social support, trauma severity, peritraumatic dissociation, and trauma frequency [22–25].”
BackgroundJ Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis
Ozer, E. J., Best, S. R., Lipsey, T. L., & Weiss, D. S. (2003) · Psychological Bulletin · doi:10.1037/0033-2909.129.1.52 · Cited by 3,322
Mild traumatic brain injury in U.S. soldiers returning from Iraq
Hoge, C. W., McGurk, D., Thomas, J. L., Cox, A. L., Engel, C. C., & Castro, C. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072972 · Cited by 2,775
Psychological theories of posttraumatic stress disorder
Brewin, C. R., & Holmes, E. A. (2003) · Clinical Psychology Review · doi:10.1016/s0272-7358(03)00033-3 · Cited by 1,132 · cited 1×
“While most traumatized individuals do not develop PTSD, the incidence of PTSD varies and is influenced by a complex interaction of individual factors such as genetic predisposition and sex, with mediating factors such as social support, trauma severity, peritraumatic dissociation, and trauma frequency [22–25].”
BackgroundSeal (2007) · doi:10.1001/archinte.167.5.476 · Cited by 936
The psychophysiology of posttraumatic stress disorder: a meta-analysis
Pole, N. (2007) · Psychological Bulletin · doi:10.1037/0033-2909.133.5.725 · Cited by 582 · cited 1×
“Studies are more consistent in showing physiological hyperreactivity following exposure to a reminder of the traumatic event [39].”
BackgroundThe diagnostic accuracy of the PTSD Checklist: A critical review
McDonald, S. D., & Calhoun, P. S. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.06.012 · Cited by 546 · cited 1×
“In general, PCL scores of 50 and above have the greatest sensitivity and specificity for trauma-related distress,* but these cutoff scores vary in different settings because of overlap of symptoms such as depression in the medical setting or TBI in the rehabilitation medicine setting [31–33].”
Backgroundde Kloet, C. S., Vermetten, E., Geuze, E., Kavelaars, A., Heijnen, C. J., & Westenberg, H. G. M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.08.002 · Cited by 503
Campbell, D. G., Felker, B. L., Liu, C.-F., Yano, E. M., Kirchner, J. E., Chan, D., Rubenstein, L. V., & Chaney, E. F. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0101-4 · Cited by 458
Cited by
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 414
Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis
GUINA, J., ROSSETTER, S. R., DeRHODES, B. J., NAHHAS, R. W., & WELTON, R. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000091 · Cited by 341
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
“BZDs have demonstrated the ability to interfere with fear extinction [17,23,39], which is critical for the improvement of anxiety and is likely why BZDs have been found to increase fear conditioning with phobias [59] and to have fear-sensitizing effects in response tostress [23,60,61].”
BackgroundInfluentialBenzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Proserpio, P., Terzaghi, M., Manni, R., & Nobili, L. (2022) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.06.004 · Cited by 4
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Metadata
- Authors
- Jeffreys, M., Capehart, B., & Friedman, M. J.
- Venue
- The Journal of Rehabilitation Research and Development
- Published
- 2012
- Volume
- 49
- Issue
- 5
- Pages
- 703
- ISSN
- 0742-3241 (ISSN-L)
- 0748-7711
- OpenAlex
- W1981983032
- Cited by
- 98
- References
- 21
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.